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ABSTRACT the review is devoted to the impact of human genome research on progress in modern medicine. Basic achievements in genome research have resulted 
in the deciphering of the human genome and creation of a molecular landmarks map of the human haploid genome (HapMap Project), which has made a tremen-
dous contribution to our understanding of common genetic and multifactorial (complex) disorders. current genome studies mainly focus on genetic testing and 
gene association studies of multifactorial (complex) diseases, with the purpose of their efficient diagnostics and prevention . Identification of candidate (“predispo-
sition”) genes participating in the functional genetic modules underlying each common disorder and the use of this genetic background to elaborate sophisticated 
measures to efficiently prevent them constitutes a major goal in personalized molecular medicine. the concept of a genetic pass as an individual DnA databank 
reflecting inherited human predisposition to different complex and monogenic disorders, with special emphasis on its present state, and the numerous difficulties 
related to the practical implementation of personalized medicine are outlined. the problems related to the uncertainness of the results of genetic testing could be 
overcome at least partly by means of new technological achievements in genome research methods, such as genome-wide association studies (GWAS), massive 
parallel DnA sequencing, and genetic and epigenetic profiling. the basic tasks of genomic today could be determined as the need to properly estimate the clinical 
value of genetic testing and its applicability in clinical practice. Feasible ways towards the gradual implementation of personal genetic data, in line with routine 
laboratory tests, for the benefit of clinical practice are discussed.
Keywords: genomics, genetic testing, multifactorial diseases, genetic passport, genome wide association studies.
Abbreviations: GP – genetic polymorphism, FGu –a functional genetic unit; Gt – genetic testing, genetic testing, MD – multifactorial diseases; GWAS – genome 
wide association studies; SnP – single nucleotide polymorphism, PS – polymorphic sites; Str – short tandem repeats; HapMap – haploid genome; Vntr – Vari-
able number tandem repeats; cnV – copy number variation.
INTRODuCTION
the revolutionary achievements in human genetics such 
as full genome seguencing, the successful completion of the 
HapMap program (haploid genome), the rapid development 
of bioinformatics and nanotechnology, advances in the dele-
lopment of efficient methods for genome analysis are signs 
of a new era: the era of genomics. the 21st century could well 
be remembered as the century of genetics [1, 2]. Impressive 
progress in comparative and functional genomics has assured 
the widespread introduction of this branch in medicine. thus, 
it has led to the emergence and rapid development of medi-
cal genomics in which such problems of classical medicine as 
diagnosis, prevention, and treatment are solved at the level 
of nucleic acids and the products of their expression: rnA 
and proteins [3, 4, 5]. the preventive direction in molecular 
medicine gave rise to predictive medicine (PM). Its main fea-
tures appear to be its individual (the genome of every human 
individual) and preventive character (analyses of the genome 
are possible at any stage of ontogeny, long before the onset of 
a particular disease). the main principles of predictive medi-
cine and genetic testing (Gt) as a methodological basis for 
PM, as well as the concept of a “genetic passport,” were for-
mulated by us in 2000 [5, 6, 37].
1 . POLyMORPHISM OF GENES AS THE 
BASIS OF PREDICTIVE MEDICINE
the genomes of all people, except for identical twins, are dif-
ferent. Pronounced population, ethnic, and, most important-
ly, individual genome features in translatable parts of genes 
(exons), as well as in their noncoding sequences (intergenic 
spaces and introns), are caused by mutations leading to ge-
netic polymorphism (GP). the latter is usually defined as a 
mendelian trait occurring in the population, at least in two 
variants, with a frequency of not less than 1% for each one 
[10]. GPs may be quantitative or qualitative.
Quantitative GP is represented by facultative elements, 
which account for up to 50% of the entire genome. these are 
micro- and minisatellite DnA, as well as DnA composed of 
tandem repeats (Str - Short tandem repeats), retrotrans-
posons, and extensive repeats with variability in core nu-
cleotide sequence composition – Vntr (Variable number 
tandem repeats). Finally, in recent years, thanks to new 
methods of DnA analysis (cnV – copy number Variation 
and GWAS – Genome Wide Association Studies), the exist-
ence of polymorphism in large DnA fragments (1-50 MGB) 
was demonstrated in the human genome; it is the so-called 
copy number Variation - cnV.
Qualitative GP is mainly single nucleotide polymorphism 
(SnP). this most frequent GP occurs roughly every 300-400 
bp. thus, the total number of SnP in the full human ge-
nome is estimated at about 10-13 ∙ 106. there is a surprising 
similarity (99.9%) in GP in the genomes of different people. 
Stable combination of several neighboring alleles – SnP on 
one strand of DnA (haplotype) – has allowed to use them as 
specific molecular markers in the program HapMap (haploid 
map) (see below).
It is assumed that about half of all SnP (5 million) are re-
lated to the sense (expressed) part of the genome. It is these reVIeWS
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substitutions that correspond to the allelic variants of genes 
that cause or are associated with various diseases. they play 
a key role in human GP [5, 7, 8, 9].
It is well known today that polymorphism is typical for 
almost all human genes. It has been established that it has a 
clear ethnic and population specificity. Polymorphisms af-
fecting the coding parts of genes often lead to the replace-
ment of amino acids and the appearance of proteins with new 
functional properties. replacements or nucleotide repeats in 
the regulatory (promoter) regions of genes may have a sig-
nificant impact on gene expression. Inherited gene changes 
play a crucial role in determining the unique biochemical pro-
file of each individual, his or her hereditary predisposition to 
various MD.
2 . HAPLOID MAP (HAPMAP) PROGRAM .
the key role in the study of GP is played by the international 
project for the study of the haploid human genome – Haploid 
Map (HapMap).
the purpose of the project is to obtain a genetic map of 
the distribution of single-nucleotide substitutions (SnP) in 
the haploid set of all 23 human chromosomes [11]]. the main 
thrust of the project consists in that the analysis of the dis-
tribution of known SnP in individuals for several genera-
tions revealed that SnPs that are adjacent or closely located 
in the DnA of one chromosome are inherited as SnP blocks. 
this block represents a SnP haplotype – a set of alleles lo-
cated on the same chromosome (hence the origin of the name 
of the project HapMap). thus, each of the mapped SnP acts 
as an independent molecular marker. By linking these SnP-
markers with the manifestations being investigated (disease 
symptoms), the most likely location of candidate genes’ mu-
tations (polymorphisms) associated with a particular MD are 
identified. typically, there are 5 or 6 SnPs closely linked with 
the already known Mendelian traits selected for mapping. 
Well described SnPs with a frequency of rare alleles of not 
less than 5% are called marker SnPs (tagSnP). It is assumed 
that, ultimately, in the process of the project’s implemen-
tation only about 500 000 tagSnP of the approximately 10 
million SnPs present in the genome of every individual will 
be selected. But this number is more than enough in order 
to map with SnPs the full human genome and identify new 
candidate genes linked with various MDs [12].
 thanks to HapMap, which includes the SnPs of not only 
already known genes, but also those of genes that have yet to 
be identified, scientists now have at their disposal the power-
ful universal navigator needed for the in-depth analysis of 
the genome of each individual for a fast and efficient map-
ping of genes whose allelic variants predispose one to various 
MDs (see below).
Francis collins, the director of the national Institute for 
the Study of the Human Genome (uSA) says: “Already 20 
years ago when discussing the program ‘Human Genome’, I 
dreamed of a time when the genomic approach will become 
a tool for the diagnosis, treatment and prevention of severe 
common diseases that affect patients overcrowding our hos-
pitals and doctors’ offices. the success of the HapMap project 
allows us to make a significant step toward this dream al-
ready today.”
3 . GENES AND HuMAN DISEASES
According to research in the prevalence of diseases in twin 
pairs and medical genetics data, only about 1.5% of human 
diseases are directly linked to mutations. these are so-called 
hereditary diseases. Accuracy in the molecular diagnosis of 
hereditary diseases is very high and approaches 100%.
All other diseases, including such frequent ones as car-
diovascular, cancer, mental, and even infectious diseases, are 
the result of the combined effect of unfavourable external 
factors and individual characteristics of the genome, some-
how predisposing a particular person to a disease. Hence, the 
origin of their name: multifactorial (combined or complex) 
diseases (MD).
thanks to full human genome seguencing, the development 
of convenient methods for the mapping of new genes (the to-
tal number of genes in humans is estimated at about 22,000), 
methods for identifying mutations, as well as the problem of 
diagnosing multiple (especially the most frequent) monogenic 
human genetic diseases (cystic fibrosis, hemophilia, Duchenne/
Baker muscular dystrophy, spinal muscular atrophy, immuno-
deficiency and others) can be considered as solved [13, 14, 15]. 
the identification of the genes involved in the genesis of MDs, 
the so-called “predisposition genes,” is much more complicated. 
According to the current definition, “predisposition genes” are 
mutant genes (alleles) that are compatible with birth and life 
but that, under certain unfavorable conditions, can contribute 
to the development of a MD [14].
Depending on participation in metabolic chains and asso-
ciations with a MD, susceptibility genes are conditionally di-
vided into several groups, among which are the genes of the 
detoxification system (“external environment”), the genes of 
metabolic bypass (genes triggers), cell receptor genes, genes 
of the inflammation and immune system, and genes associ-
ated with a specific MD [Baranov, 2000, Baranov et al, 2000]. 
unfavorable allelic variants of these genes can cause athero-
sclerosis, coronary heart disease (cHD), osteoporosis, diabe-
tes, asthma, tumors, etc. the combinations of allelic variants 
of different genes that provide normal metabolic processes or 
are involved in the development of a specific multifactorial 
pathology are called “gene networks”[16]. In each of these 
networks, the main (central) genes and additional (auxiliary) 
genes (the so-called genes modifiers) are defined. the concept 
of genetic networks has further evolved to the study of func-
tional genetic modules (FGM). to this end, a series of studies 
have compared the MDs and the various genes whose prod-
ucts are involved in the etiology and pathogenesis of these 
diseases [17, 18, 19]. A network of MDs and the genes common 
to these diseases was created and named the human disease 
network (HDn) (Fig. 1) and, vice versa, a network of genes 
common to various diseases – disease genetic network – DGn 
(Fig. 2) has also been created. combining HDn-and DGn-
maps has made it possible to create the so-called diseasasome 
map that reflects the topology of metabolic networks and the 
genetics of MDs (Fig. 3). As a result of a large-scale study of 
1,264 MDs and their associated 1,777 genes [17], the following 
has been established: 1) each MD is characterized by its own 
set of genes – a gene network or so-called functional gene 
modules (FMG), there are central and peripheral genes that 
can be distinguished by module; 2) most MDs are intercon-
nected through many different genes; 3) 516 MDs show a lot 72 | ActA nAturAe |  № 3 2009
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of genetic linkages; ie, they are associated with many genes 
(deaf - 41 genes, leukemia - 37, cancer of the colon - 34); 4) the 
mutation of different genes can lead to the same MD, and mu-
tations (polymorphisms) of one gene may be associated with 
different MDs; 5) the mutation of the central (essential) genes 
of FGM are often associated with tumors and causes early 
death; 6) mutations (polymorphisms) of the peripheral FMG 
genes play a major role in the phenotypic variability and the 
development of MDs; 7) the presence of overlapping FGM of 
MDs shows the pathogenetic proximity of different MDs and 
argues in favor of syntropy – a combination of pathogeneti-
cally related, “family,” of MDs; and 8) genes included in FGM 
are essentially “syntropy” genes [20] which are functionally 
similar but not always identical to “predisposition” genes. 
the coincidence of many MDs in a large number of associated 
genes was clearly demonstrated when comparing candidate 
genes associated with various autoimmune diseases (Fig. 4).
About a third of the identified loci are associated with 
two, three, or more diseases. the presence of more than 5% of 
common candidate genes associated with the celiac disease, 
crohn’s disease, multiple sclerosis, psoriasis, rheumatoid ar-
thritis, systemic lupus erythematosus, diabetes mellitus type-
1, and ulcerative colitis proves the pathogenetic similarity of 
these autoimmune diseases [21, 22] and allows one to consider 
them as a single group of sintropy diseases.
clarification of th eFGM of each MD, identification of the 
central genes and modifier genes in it, the analysis of the as-
sociation of the alleles of these genes with the disease, devel-
opment of a set of preventive measures for persons at high 
risk and, subsequently, for a particular patient on this basis is 
the main focus of predictive medicine [5].
4 . SEARCH STRATEGy FOR “PREDISPOSITION” GENES . 
In past decades the search for candidate genes has been per-
formed by means of two approaches: the analysis of associa-
tion and analysis of linkage.
Circles – diseases; the size of the circle is proportional to the 
number of the known candidate genes involved in MD.
Lines – the candidate genes associated with different MDs, the 
line’s thickness is proportional to the number of common genes. 
The number of genes – the scale of genes involved in MDs
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Fig.1. Gene networks of some common multifactorial (complex)  
disorders Fig.2. Functional genetic modules of different MDs
Circles – diseases, lines – common genes; the size of circle and line’s 
thickness are proportional to the number of associated genes.
Rectangles – genes; lines – genetic linkage common to different MD.
Diseasasomes – the combination of phenotype (MD) with correspond-
ing marker genes 
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Fig.3. The topology of metabolic networks and the genetics of complex 
disorders
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Fig. 4. The number of loci common to autoimmune diseases, and loci that 
are specific to a particular disease
Conventional signs: C – celiac disease, CD – Crohn’s disease, MS – 
multiple sclerosis, P – psoriasis, RA – rheumatoid arthritis, SLE – sys-
temic lupus erythematosus, T1D – type 1 diabetes, UUC – unspecific 
ulcerative colitis
Circles – diseases; the size of the circle is proportional to the number 
of diseases associated with a candidate gene.
Lines – the linkage between genes common for different diseases.
Diseases – the scale of studied diseases; color – the type of disease; 
gray color – the gene is associated with many MDs.
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the basis of the method of analysis of the association is 
the disequilibrium in the linkage between the mutation and 
the nearby marker tested [23]. the method involves several 
steps: 1) selecting the most probable candidate genes on the 
basis of the particular disease, 2) the selection of function-
ally important alleles of the corresponding genes, 3) a popu-
lation analysis of the allele and genotype frequencies of the 
corresponding genes on the basis of literature data and the 
Internet, and 4) a comparative analysis of allele frequencies 
and genotypes of these genes in patients with a clinically con-
firmed diagnosis and in healthy individuals of the same popu-
lation, matched by the type of “experience-control.”
Studies are conducted on representative samples of pa-
tients and donors (at least 100 people in each group).
Obviously, such a way, being quite lengthy, laborious and 
costly, at the same time does not guarantee that the identified 
allelic differences are the main ones in the chain pathogenetic 
mechanisms involved in the particular disease. It does not rule 
out the fact that some important genes and polymorphisms of 
the same, or even more, or another gene network involved in 
the disease can be missed, and that clinically different forms 
of the disease under study may have a different pattern of 
candidate genes.
An alternative strategy of searching for predisposition 
genes (linkage analysis) is based solely on the positional clon-
ing of locus and does not require a preliminary hypothesis 
about the pathophysiology of the disease. Initially, the meth-
od of genome-wide linkage study (GWLS) was the one avail-
able and widely used. the GWLS method is used in families 
with several sick siblings or in extended pedigrees. It is aimed 
at detecting in patients blocks of molecular markers that are 
passed from parents to sick descendants but not to healthy 
ones. the method allows to localize the gene on the area of 
1-10Mb. these extensive areas of chromosomes usually in-
clude hundreds of genes; thus, the search for the causative 
gene in linked locus is a difficult and often impossible task.
 today, a more advanced and widely used method is the 
method of Genome Wide Association Studies (GWAS). this 
method was a breakthrough in genetic studies of MDs. It is 
based on using the HapMap program in conjunction with the 
technique of high-resolution biochips. As a result of the Hap-
Map Project, the distribution of thousands of polymorphic 
sites - single-nucleotide substitutions (SnP) was revealed 
in the human genome and haplotype maps were created – 
maps of stable combinations of SnP variation within a single-
stranded (haploid) DnA sequence [13]. Another important 
technical achievement was the hybridization of high-density 
DnA biochips that enabled simultaneous genotyping of thou-
sands of SnP sites in one DnA sample. With knowledge of 
the exact position of each SnP on the physical map of the 
haploid genome, it has become not only possible to identify a 
candidate gene, but also to identify all SnPs associated with 
MDs [24, 25].
 the basis of the GWAS method is in the scanning of hun-
dreds of thousands of markers located on all human chro-
mosomes. thanks to the haplotypes maps obtained in the 
HapMap project, modern chip design includes the maximum 
number of key SnP (tag SnPs) and permits to estimate the 
frequency of both individual markers and haplotypes for the 
entire length of the DnA molecule. For example, the wide-
ly used chip firm Illumina (www.illumina.com) comprising 
310,000 tag SnPs (Illumina Hap310K) enables to estimate the 
frequency of 81% of frequent polymorphisms in the europe-
an population. the next development by the same company 
comprises 550,000 SnP (Illumina Hap550K) and covers more 
than 90% of frequent polymorphisms [24].
Genome-wide associations screening is conducted on a 
large number of patients and controls (more than 1,500 – 
2,000 people), which ensures highly reliable (p <0.000005) 
results and includes several stages. At first, hundreds of as-
sociations are identified, most of which appear to be false-
positive after hundreds of thousands of independent tests. 
In the next step, associations in an independent cohort of pa-
tients and controls are analysed by the same method. Only the 
results confirmed in a replication cohort are considered to be 
reliably positive. At present, the scanning of about 300 differ-
ent associations of MDs has been carried out by using GWAS. 
the results of these studies are summarized on the website 
of the national Institute of Health (uSA) - http://www.ge-
nome.gov/GWAstudies/index.cfm? # 1. the data include the 
results of GWAS obtained with a reliability of p <1 ∙ 10-5 and 
containing not less than 100,000 SnP. they are regularly up-
dated following each publication of new data [25].
GWAS in complex diseases is very popular and has been 
successfully used in the past few years. Data obtained for 
genes associated with certain diseases of the immune system 
are presented in Fig. 5.
 thus, the GWAS method is surely becoming the principal 
method for the search for candidate genes of all MDs. unfor-
tunately, this revolutionary technology, to my knowledge, so 
far remains hardly available in russia. Given the significant 
populational differences in genetic polymorphism, the imple-
mentation of GWAS technology for the identification of can-
didate genes of MDs in this country is of utmost necessity. 
5 . GENETIC PASS 
Many diagnostic centers in russia currently widely use mo-
lecular methods for the diagnosis of genetic diseases and de-
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Fig. 5. Progress in searching for genes of MD of immune system.
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tection of heterozygous carriage of pathological mutations in 
families at high risk for the preliminary diagnosis of diseases 
with a late manifestation and for personal identification (ge-
nomic fingerprinting). Gradually, genetic testing for predic-
tive medicine is gaining in strength. Obviously, data on both 
the genome of individuals and entire families and, gradually, 
individual and family DnA databases are being created. Such 
an individual DnA database is a “genetic passport (pass).”
thus, a genetic passport is an individual DnA database 
reflecting the unique genetic characteristics of an individual, 
his or her predisposition to some hereditary, multifactorial 
and other diseases [4, 5, 6, 37].
the information contained in this really unique document 
should help to avoid the difficult situations in one’s life as-
sociated with ignorance of the individual characteristics of 
one’s genome; ie, the specific characteristics of one’s heredity. 
these data allow us to more fully fulfill our genetic ability 
and are of undeniable value for progeny.
the widespread introduction of molecular diagnostics in 
modern medicine has already made real the idea of a genetic 
passport. It is already a de facto reality, and the number of 
Gt is increasing rapidly. However, launching the establish-
ment – and especially the practical use – of genetic passports 
can only be allowed with fairly stringent regulatory require-
ments. the latter include the following:
1. a well studied genetic network for each MD;
2.   reliable clinical and population data confirming the con-
tribution of relevant marker genes in the pathogenesis of 
MD;
3.   representative data for the population of a particular re-
gion or the ethnic group demonstrating the association of 
the tested marker genes with the MD;
4.   a well-balanced (adequate) interpretation of Gt results in 
hereditary predisposition;
5.   cogent recommendations based on the results of Gt (ac-
cording to the genetic passport);
6.   monitoring of the remote results of the patient’s condition 
after Gt and the prescription of recommendations by clini-
cal geneticists; and
7. privacy, accessibility, and legal protection for patients.
the full version of a genetic map should include not only 
a study of predisposition genes, but also asymptomatic car-
rying of mutations of genes of the most common hereditary 
diseases (hemophilia, cystic fibrosis, phenylketonuria, etc.). 
currently, the existing molecular diagnostic laboratories in 
russia, including those located in St. Petersburg, allow for a 
fairly complete set of essential genetic tests. One of the first 
variants of a genetic passport was proposed by us in 1997 
(Fig. 6)
At present, practical applications are found for only some 
components of a genetic passport (heterozygous carrier test-
ing, genomic fingerprinting, and karyotyping). rarely, and 
only in high-risk families, is hereditary predisposition to 
bronchial asthma, diabetes, or osteoporosis tested.
the genetic map of reproductive health appears to be 
more advanced as regards its clinical implementation. Such a 
map was obtained as a result of many years of comprehensive 
studies of the reproductive function of women conducted at 
the Ott’s Institute of Obstetrics and Gynecology rAMS (St. 
Petersburg) [26]. the map is recommended for use in family 
planning centers, as well as in antenatal and other centers 
of the institute. It is widely used in outpatient counseling by 
clinical geneticists and obstetricians in our institute. In addi-
tion to karyotype analysis and testing for a carrier of muta-
tions of severe hereditary diseases for spouses who are plan-
ning to have a child, the screening of women for an array of 
genetic diseases complicating pregnancy, fetal development, 
childbirth and the postpartum period (pre-eclampsia, ha-
bitual miscarriage, varicosity, feto-placental failure) has an 
important prognostic significance (Fig. 7). For gynecologists 
and endocrinologists, testing of genetic susceptibility to en-
dometriosis, adenomyosis, and postmenopausal osteoporosis 
is of great interest.
 Particular attention is focused on the testing of heredi-
tary forms of thrombophilia, for diagnostics of which a special 
microbiochip called “Fibrochip” was developed [27]. the clini-
Fig. 6. A version of the “genetic passport” [5,6] Fig. 7. A version of the “genetic card of reproductive health” [26]
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carriers testing: 
• cystic fibrosis
•   Deuchene muscle 
dystrophy
• hemophilia A
•   phenylketonuria
•   adreno-genital 
syndrome
•   spinal muscular 
atrophy
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•   pre-eclampsia GSTPi; PAI-
1,TNF-ά; eNOS; ACE; PON; GP-
IIIa., HLA-G GSTV-1, mEPHX
•   habitual miscarriages GSTM1; 
GSTT1; GSTPi. ; DRB1; DQA1, 
DQB1, MTHFR
•   diabetes type 1 HLA DR и DQ (DR3 
and DR4) Mic-A;, VDR3  CTLA4
•   diabetes type 2 DQB1, ACE , TNFα  
PRARA, PRARD, TCF7L2
•   endometriosis GSTT1; GSTM1; 
CYP19 miEPOX, NAT-2 TNFα; 
IL4R; CYP1A1 
•   osteoporosis VDR 3; COL1A1; 
CALCR; ER -1
•   bronchial asthma GSTT1 GSTM1 
TNFA, IL4, IL4R, Nos1
•   meiotic chromosome non disjunc-
tion and neural tube defects  
MTHFR;  MTTR.
Concluding medical genetic consulting, 
information for the obstetrician and 
patient, feasible practical  
recommendations 
Date of birth - 1997
Place of birth - Peterhoff    
Strictly confidential
Karyotype
Presymptomatic testing:
1.   Neurodegenerative 
disorders: HD; SCA1; 
DRPLA; AR; SCA2;
2.   Familial breast cancer: 
BRCA1; BRСA2  
colon cancer: APC.
3.   Alzheimer disease: 
PS-1; PS-2.
Primary genetic 
counseling
Heterozygous 
carriers testing: 
• cystic fibrosis
•   Duchene muscle 
dystrophy
• hemophilia A
•   phenylketonuria
•   adreno-genital 
syndrome
•   spinal muscular 
atrophy
Genetic predisposition testing: 
•   osteoporosis VDR3; COL1A1; 
CALCR
•   lung cancer GSTM1; GSTT1; 
NAT-2; CYP1A1; p53-6; p53-16; 
p-53-72
•   breast cancer GSTM1;GSTT1; 
GSTPi; L-MYC;NAT-2; CYP1A1; 
CYP17; CYP19; p53-6; p53-16
•   colon cancer GSTM1; NAT-2; 
GSTT1
•   diabetes type 1 HLA DR and DQ 
and DR4; DR3; Mic-A; VDR-3
•   cardiac ischemic disease ApoE; 
MTHFR ; PON FV; FVII; ACE
•   hypertonic disease AGT; PAI1; 
АСЕ, ANT; Apo C, ApoB-100
• alcohol abuse DRD3; DATI
• narcomany DRD2A; DRD2
•   inherited thrombophilia MTHFR, 
FV, PAI-1, FGB, GPIIIa/b, FII
•   AIDS resistance 32delCCR5/+
Concluding medical genetic consulting, 
information for the physician and patient, 
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cal trials of the genetic map of reproductive health (GMrH) 
conducted at the Ott’s Institute of Obstetrics and Gynecol-
ogy, rAMS, focused primarily on individual disorders, such 
as endometriosis (prognosis and choice of optimal treatment 
tactics), inherited thrombophilia factors, miscarriage and 
placental insufficiency, and gestosis (prediction and preven-
tion). the accumulated information on the genetic markers 
of obstetric pathology that results from prospective testing 
is a good reason for a wider implementation of such a card 
(GMrH) in clinical practice.
Based on WHO recommendations, genetic testing should 
be carried out with the voluntary, informed consent of the 
patient; ie, after he or she reaches adulthood. Formally, this 
means that important genetic information could become 
available relatively late, when its benefits to the subject and 
his close relatives have largely been lost. However, taking into 
account the importance of these data for children’s health, 
the harmonious development of their personality, rational 
nutrition, effective education, athletic training, optimal prof-
fessional guidance, and the opportunity to prevent the devel-
opment of several diseases with a late manifestation, intro-
ducing genetic passports at an early age would seem to make 
sense today. A possible genetic map of a child based on the re-
sults of studies of his gene associations is shown in Figure 8.
It cannot be excluded that as the ethical and social prob-
lems associated with studies of the human genome are solved 
genetic testing in an earlier than currently recommended 
age will become common. In any case, in families with a high 
risk of diabetes type-1, asthma, sudden death due to cardiac 
conduction and rhythm disorders, metabolic syndrome and 
obesity, as well as several other nosology, preventive genetic 
testing at an early age seems reasonable. [37]. Obviously, the 
testing should only be conducted with parental consent, with 
recommendations from a pediatrician, and after consultation 
of the family by a clinical geneticist competent in predictive 
medicine.
Likewise, information about gene markers, the testing of 
allelic variants of which allows to evaluate the suitability of a 
teenager to a particular sport, accumulates rapidly. current-
ly, information is available about nearly 150 different genes 
that control human physical development. that is important 
for proper fitness and for the selection of potentially promis-
ing athletes. the obtained results allowed to start building an 
individual version of the genetic map of the athlete, which 
includes the testing of certain genes that determine human 
physical characteristics.
 Despite certain limitations of legal, moral and ethical char-
acter, a lack of information on the gene networks of various 
metabolic processes and multifactorial diseases, the lack of 
reliable statistical information and the imperfection in the 
clinical interpretation of the results of genetic testing, the 
creation of a functioning genetic passport of some type for 
citizens should be welcomed. Such a medical document can be 
of substantial assistance during the examination of the health 
status of an individual, as well as in assessing the potential 
risk of developing a particular disease by members of a fam-
ily at high risk of developing an MD [37].
thus, despite the obvious imperfections of modern predic-
tive medicine, genetic screening of families at high risk for 
some serious MDs, as well as professional athletes and people 
exposed to extreme work conditions and individuals simply 
interested in information about their genome, seems quite 
real. Obviously, a genetic map of reproductive health is also 
of great practical significance.
6 . THE MAIN PROBLEMS RELATED TO GENETIC TESTING OF MD
testing for gene associations, i.e. the search for candidate 
genes coupled with a variety of MDs, is already widespread 
throughout the world, including at leading laboratories and 
genetic centers in russia. According to international reports, 
thousands of polymorphic sites are tested daily to determine 
associations with diseases [28]. About 100 major candidate 
genes, each of which contains several polymorphic sites that 
affect the function of the gene and its products, have already 
been identified or are under study for common MDs.
the GWAS method in searching for marker genes of MDs 
has become more widely used in recent years [29]. Hundreds 
of candidate genes and anonymous polymorphisms coupled 
with the most common MDs have already been identified us-
ing this method [29]. comparison of the characteristics of the 
distribution of allelic variants in patients and healthy people 
has already led to the definition of the “genomic profile” of 
a MD that corresponds to the SnP-alleles distribution in the 
genome typical of a particular disease. thus, identification 
of marker genes in itself appears not to be important. the 
results are written using the numbers of tagSnP that have 
shown reliable linkage with the MD. For example, 22 variants 
of the genomic profiles of risk of prostate cancer were identi-
fied in a large prospective study of the Icelandic population. 
the highest linkage (Or = 1.23; P = 6.7 ∙ 10-12) was found for 
SnP rs11228565 of locus 11q13. the presence of four vari-
ants of the risk SnP rs10934853 (3q21.3), rs16902094, and 
rs445114 (8q24.21) rs8102476 (19q13.2) increased the prob-
ability of prostate cancer in carriers by 2.5 times compared 
with population SnP variants [30]. commercial genetic tests, 
including “individual genomic profiles,” have emerged and 
are been actively promoted by various diagnostic centers 
in America (celera, Myriad genetics, Decode, navigenics,  Fig. 8. A version of the “genetic card of a child’s health” [37]
Date of birth - 
Nationality - 
Karyotype
Primary genetic 
counceling
Heterozygous carriers  
testing: 
• cystic fibrosis
•   Deuchene muscle  
dystrophy
• hemophilia A
• phenylketonuria
• adreno-genital syndrome
• spinal muscular atrophy
Genetic predisposition testing: 
•   bronchial asthma GSTМ1, GSTT1, GSTР1, 
СС16, IL4, IL4R, NOS1, TNF- α
•   diabetes type 1 DQA1, DQB1, MIC-A, 
CTLA4
•   arterial hypertension ACE, AGT, AGTR1, 
AGTR2, BkR, REN, ADRB2, ADRB1, 
MTHFR, NOS3, MTRR, ApoE, ApoCIII, 
PRAR–γ
•   inherited thrombophilia MTHFR, FV, PAI-1, 
FGB, GPIIIa/b, FII
•   metabolic syndrome ApoE ApоCIII, AGT, 
ACE, AGTR1, AGTR2,BKR, REN, ADRB1, 
ADRB2, DQB1, TNFA, DRD-2A, SR, IGF1, 
PRAR–δ, PRAR–α, PRAR–γ, UCP2, UCP3
• t  ransplantology CYP2D6, CYP2C9, 
CYP2C19, TPMT/HLA
•   testing predisposition to alcohol abuse and 
narcomany DRD-2A, SR
•   resistance to AID infection  DRD-2A, SR
Concluding medical genetic 
consulting of the parents,  
information for the physician 
patient, feasible practical  
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23andme) and Western europe (Sciona, Gendia) [31].Yet the 
associations of numerous marker genes and polymorphic loci 
with a particular disease remain unproven, and more than 5% 
of already identified associations turn out to be random [28]. 
In the opinion of many experts in molecular medicine and 
medical genetics, a quite alarming situation is developing as 
commercialization and business become the primary motive, 
instead of science.
the main problems that have appeared in the implemen-
tation of Gt results of hereditary predisposition to clinical 
practice are as follows:
1.   the completeness of identification of all candidate genes of 
the gene regulatory network (FGM) of MD;
2. proofs of the reliability of their association with MDs;
3. medical evaluation of Gt results; and
4. the clinical significance of predictive Gt. 
6 .1 . THE COMPLETENESS OF THE IDENTIFICATION OF 
CANDIDATE GENES FGM FOR A PARTICuLAR MD
the method of analysis of association (see Section 3) at best 
permits to reveal the most obvious, in terms of the pathogen-
esis of the disease, candidates genes and conduct a compara-
tive analysis of allele frequencies in cohorts of patients and 
population controls.
the method of genome-wide linkage analysis allows for a 
more detailed identification of loci coupled with a specific MD, 
but the rather extended size of these loci often highly compli-
cates the exact identification of important candidate genes in it.
today, hope in solving this problem rests on the GWAS 
method. using high-density biochips (over 500,000 SnP) allows 
to overlap the full genome with high reliability. thus, informa-
tion on all the SnP linked with MDs can be obtained. However, 
many such associations appear to be random in fact and can be 
discriminated only by repeated GWAS analysis conducted on 
other cohorts of patients with the same MD and other groups 
of population control. In addition, the association in one or an-
other DnA site does not always coincide with the presence of 
the corresponding candidate gene in it and does not necessarily 
mean the identification of the mutations responsible for the 
predisposition to the MD. In most cases, the identified SnP sites 
are located in intergenic DnA and, in fact, can be considered 
only as a molecular marker linked with one or several neigh-
boring genes. However, at the moment the GWAS method, 
when complemented by the sequencing of linked loci and the 
analysis of the expression of its constituent genes, is considered 
as the most effective method for identifying candidate genes 
comprising FGM of a particular MD. However, the identifi-
cation of new marker genes associated with the MD is often 
paired with the revision of the value of the initial individual 
risk. that was clearly illustrated in the genomic scanning for 
predisposition to type 2 diabetes [32].
the possibility of testing for hereditary predisposition not 
only on the basis of the allelic variants of predisposition genes, 
but also for the genomic profile on the basis of tagSnP [30] 
significantly bolters the case for predictive medicine.
6 .2 . THE RELIABILITy OF THE ASSOCIATION OF 
CANDIDATE GENES WITH A SPECIFIC MD
currently, there are already about 1,024 clinical genetic tests 
of MDs and there are more than 300 genetic tests that are in 
the pre-clinical and clinical trials stages [33]. For many MDs, 
some “major” genes have already been identified. their in-
volvement in a particular pathology has been confirmed by 
research on representative groups of patients in many labo-
ratories. Such MDs include, for example, Alzheimer’s disease 
(ArOe4), type-2 diabetes (PPArG, tcF7L2, KcnJ11), se-
nile macular degeneration of the retina (cFH), systemic lu-
pus erythematosus (JrF5), prostate cancer (region JF1H), 
type-1 diabetes (IL2rA, cD25, PtPn22), autoimmune thy-
roiditis (ctLA4), hirschsprung disease (ret), crohn’s dis-
ease (nOD2, cArD15), and rheumatoid arthritis (PtPn22) 
[8, 34]. nevertheless, the attitude toward Gt remains quite 
skeptical, largely because of the absence of definite statistical 
evidence of the reliability of Gt results.
One important reason for such a discrepancy is the relative-
ly small sample groups of sick and healthy patients. At best, 
they are limited to hundreds of subjects, whereas a compara-
tive genetic analysis of several thousands of healthy and sick 
patients is required to obtain statistically reliable data [28].
Populational differences in allelic frequencies for the same 
candidate gene could be another reason for the variability 
of gene associations. non-randomly identified allelic differ-
ences demonstrating the significance of a particular associa-
tion are often averaged and become statistically insignificant 
when combined with data from different works carried out 
on groups of patients, and controls of other populations.
the need for large sample groups is dictated by the rela-
tively low rate of relative risk, Or, which shows how much 
more common is the studied disease in individuals to study 
the disease with a specific allele or set of different alleles of 
the marker genes, compared with individuals with other al-
leles of the same candidate genes [35]. typically, for known 
gene markers associated with an MD, the value of Or does 
not exceed 1.5 and is usually within 1.16-1.2. thus, the com-
bination of several unfavorable alleles of candidate PtPn22 
in diabetes and systemic lupus erythematosus and the nOD2 
gene in crohn’s disease increases the relative risk of the dis-
ease (Or) 2-3 times. For most other associations, Or ranges 
from 1.1 to 1.5. [22]. therefore, the real contribution of each 
marker gene in the development of the MD is relatively small. 
therefore, for definite proof of association extensive genetic 
studies are required. It is believed that to prove a 90% prob-
ability of any association between a gene and disease with 
an Or equal to 1.25, the study requires 5,000 patients and a 
control group of not less than 5,000 people. this is assumed 
to increase the level of significance (p <0.00005 instead of 
the usual p <0.05) 10,000 times [28]. the appearance of the 
GWAS method has radically changed the situation as relates 
to the problem of predictive validity of Gt. thus, in assessing 
the risk of myocardial infarction by Gt of 85 SnP in corre-
sponding candidate genes, the reliability of associations has 
increased to p <0.0000001 [36].
Another important factor that proves the strength of iden-
tified association is its replicativeness; ie, the reproducibility 
of Gt in the works of other researchers.
the reasons for the variability of genetic polymorphism 
are very diverse.
- Genetic stratification of the studied population (the pres-
ence of subpopulations with different initial frequencies of 
the analyzed alleles in it) [28];reVIeWS
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- Allele frequencies in different populations may vary, and 
their contribution to the pathogenesis of a specific MD could 
be different;
- Pathogenetic differences in a MD could be due to the pe-
culiarities of the action of various external factors in different 
geographical conditions;
- the inaccuracy of the clinical diagnosis could lead to er-
rors in the formation of clinical sample groups; 
- Alleles associated with the same MD in different popula-
tions could be different.
there are several other factors that substantially hinder 
the correct evaluation of the observed genotype-phenotype 
association, even if it is quite statistically significant:
- the identified association cannot relate to an identified 
gene or SnP-marker but to a gene or locus (alleles) that is 
closely linked with a yet unknown locus or allele, whose prod-
uct is involved in the pathogenesis of MD;
- the identified association could, in fact, be not related 
to the candidate gene in itself but to another gene product 
which functionally compensates for the effect of the mutant 
gene (epistatic relationship of genes);
- not only gene--gene interaction remains very poorly 
understood, but also the interaction of candidate genes with 
environmental factors;
- the pathogenesis of any MD can often be the result of 
disorder in the function of not just one, but different gene 
networks;
- Along with the typical polygenic forms of a MD, there are 
also common forms of monogenic (osteoporosis, Parkinson’s 
disease, Alzheimer’s disease, various cancers) MDs[35].
Obviously, all these factors significantly complecate the 
correct identification of marker genes and the assessment of 
their objective contribution to the pathogenesis of the dis-
ease.
recognizing all these limitations and the very real diffi-
culties in the identification of the marker genes of MDs, it is 
important to pay attention to the following circumstances:
- All MD genotype--phenotype relationships always have 
a stochastic nature and are not strictly determined; ie, accu-
racy in the DnA diagnosis of MDs, in contrast to monogenic 
diseases, never approaches 100%.
- Groups of sick and healthy patients will include thou-
sands of people in an analysis using the GWAS method, which 
ensures a high reliability of the results.
- the overwhelming majority of marker genes and loci 
identified with GWAS usually includes associations previ-
ously established by other methods.
these statements need further clarification and verifica-
tion, but they already provide a basis for more extensive pre-
clinical and clinical trials of the already identified candidate 
genes of common MD.
At the current stage in development of predictive medicine 
in russia, it seems rational to compare the known candidate 
genes of MDs identified in the works of local researchers with 
the corresponding panels of candidate genes identified using 
GWAS (1), to test the allele frequencies of the main new can-
didate genes on already existing samples of patient-healthy 
DnA-banks (2), and to create of a new panel of genes of MDs 
based on the data obtained (3).
6 .3 . EVALuATION OF THE RESuLTS OF PREDICTIVE GT
the evaluation of genetic testing results should be conduct-
ed considering already existing knowledge about the gene 
networks of specific MDs, the population, gender, and age 
characteristics of the frequency of polymorphic alleles of 
the studied genes [37]. considering the probabilistic nature 
of forecasts based on the genetic testing of hereditary pre-
disposition to MDs, some assistance in assessing the risk of a 
hereditary predisposition can already provide a fairly simple 
method of score evaluation, which is used in some western 
countries (Harvard School of Public Health) and is already 
used in some russian centers conducting genetic testing [38, 
39, 40]. the essence of the method is as follows: each geno-
type variant is estimated on conditional points depending on 
whether the alleles identified are protective or predispose to 
the development of pathology. to this end, alleles with altered 
functional activity of the gene are assigned 1 point, while nor-
mal (frequent), wild-type alleles are assigned 0 point. then, 
the points corresponding to genotype for every tested can-
didate gene are recorded, summed up, and divided by the 
number of tested genes. So, the risk of developing the disease 
could be conditionally evaluated as medium, low, or high. In 
the presence of pathogenetically complex MDs, including sev-
eral different metabolic chains, the calculation is conducted 
for each gene network separately and the estimates obtained 
are added up. Some variants of score evaluations, in addi-
tion to the calculation of points corresponding to genotypes, 
also include conditional points of various exogenous factors 
(harmful effects, habit, medication intake, etc.), anthropo-
metric values, as well as physical activity, sex, weight [26].
Information on the basis of Gt results is prepared by a 
clinical geneticist, together with the specialist who carried 
out the molecular analysis, and is passed along to the physi-
cian and patient. comparison of this conclusion with the re-
sults of clinical, laboratory, and instrumental investigations 
permits to assess the risk of developing a MD more objec-
tively and to offer the most effective program of prevention 
and treatment.
the answer may be more objective if it is possible to com-
pare the results with data on the genetic testing of a close rel-
ative who has a given MD. But in any case the answer would 
be essentially probabilistic in nature. A detailed method of 
scoring the results of Gt is given in our user guide devoted to 
the genetic map of reproductive health [26].
Special computer programs could significantly assist in the 
correct interpretation of Gt results. Such programs are avail-
able and are used to compare the genomic profiles of patients 
with MDs, the control group of patients, which allow us to 
estimate the risk of hereditary predisposition of a particular 
person to a MD [29]. A map is created that facilitates the un-
derstanding of the results of Gt by the medical staff. It helps 
to find genetic variations corresponding to certain diseases 
and to monitor their transmission by inheritance. It is be-
lieved that such a map will help to reduce the cost of search-
ing for genes of predisposition to a particular MD, as well as to 
make real development of individual treatment possible [41]. 
there is no doubt that the establishment of such a computer 
program to evaluate Gt results in russia would also greatly 
accelerate the introduction of predictive medicine in clinical 
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According to foreign reports, Gt for assessing genetic 
susceptibility to cardiovascular diseases, venous thrombosis, 
hyperlipidemia, and atherosclerosis has already been devel-
oped and is widely used [41]. It is important to emphasize that 
these studies have yet to acquire the status of tests recom-
mended for clinical use, but they are already being used by 
clinicians. More than 1,000 predictive Gt, many of which are 
at the pre-clinical and clinical trials stages are in the same 
state. the objects of Gt are such genes as APOe4, homozy-
gosity for which increases the risk of Alzheimer’s disease 14-
fold; gene Filaggrin, mutation in which r501X or 2282del14 
increases the risk of atopic eczema and severe asthma 4-fold; 
the unfavourable alleles of cDKn22a2b (64% increase of risk 
of infarction by 64%); and 4a/4b alleles of In, the presence of 
which doubles the risk of type 2 diabetes. However, the clini-
cal significance of these genetic tests remains unclear; their 
usefulness to physicians and patients needs more rigorous 
proof [36].
the first predictive genetic test to calculate the individual 
dose of the anticoagulant warfarin successfully passed cer-
tification and received the formal approval of the u.S. Food 
and Drug Administration on August 16, 2007. the test in-
cludes testing of the genes cYP2c9 and VKOrc1, taking into 
account the age, sex and weight of the patient.
In 2008, the euroGentest commission in europe developed 
guidelines for Gt standardization and prepared the necessary 
documentation for certification of those genetic tests that, on 
the basis of the results of clinical trials, can be referred to the 
category of GtB recommended for clinical use [nippert et 
al., 2008].
6 .4 . RECOMMENDATIONS ON THE 
RESuLTS OF GENETIC TESTING
Gt may offer real benefits only if it is accompanied by full 
consultation with a qualified clinical geneticist, with the 
provision of relevant recommendations to the physician and 
patient. Gt may have practical value if the following con-
ditions are fulfilled: (1) the results of Gt are based on the 
analysis of genes whose association with the corresponding 
disease is shown in the population of the particular region; 
(2) the subject is a family member at high risk, where there 
is already a patient with this pathology; and (3) the Gt data 
are subjected to adequate statistical analysis. effective use 
of such information is largely determined by the level of 
genetic knowledge of physicians, their ability to apply the 
data to the diagnosis, prevention and treatment of diseases, 
as well as the willingness of the patient to follow the rec-
ommendations of physicians based on the results of genetic 
testing. [39]. But even under these conditions, Gt results 
concerning hereditary predisposition should be interpreted 
very cautiously. When possible, Gt should be complemented 
with an appropriate biochemical analysis allowing to evalu-
ate the functional activity of the studied genes. It should be 
required that more objective information be obtained by 
testing the genes controlling only a single metabolic proc-
ess; ie, the genes belonging to the same gene network. thus, 
already today on the basis of genetic testing the functional 
conditions of the following systems can be assessed objec-
tively: the detoxification system, blood coagulation, lipid or 
carbohydrate metabolism, the renin-angiotensin system, 
and others. Assessing the outcome and prognosis of hered-
itary predisposition to MDs caused by damage to several 
gene networks is much more difficult.
the main difficulties in the widespread implementation 
of predictive medicine in clinical practice are related to the 
lack of objective data to prove the usefulness of preliminary 
(no symptom) testing of hereditary predisposition to MDs for 
the patient.
According to the Gene Dossier recently developed by the 
united Kingdom Genetic testing network (www.ukgtn.nhs.
uk), certification of each new Gt should include (1) informa-
tion on the analytical precision of the used molecular genetic 
methods; (2) the clinical reliability of the Gt, i.e. its ability to 
diagnose or predict the presence or absence of a certain phe-
notype; (3) the clinical usefulness of Gt, its compliance with 
ethical, legal and social norms, which means that Gt should 
be aimed at specific populations and serve to solve a particu-
lar problem (www.labtestonline.org.ru).
the British fund Wellcome trust, which initially funded 
the Human Genome Project program, in 2008 began support-
ing a project aimed at improving and strengthening the evi-
dence base of genetic testing, as well as the development of 
a handbook for the coordination and integration of Gt into 
clinical practice with sufficient explanations of their useful-
ness to physicians and patients. At the same time, the estima-
tion of the clinical usefulness of Gt is equivalent to phase III 
of clinical trials, but it remains unclear whether Gt should 
be paid for by governments or the firms working on and ad-
vertising Gt [43].
the ultimate goal of the project is to move predictive med-
icine from the field of research of genetic polymorphism fea-
tures and identification of genes - markers of MDs to the level 
of evidence-based medicine.
the results of every Gt should include not only informa-
tion about the features of the allelic variants of the genes of 
a metabolic chain, but also recommendations for the patient 
and physician [44]. A “Genetic” reorientation of the health 
care industry is already happening in the developed countries 
of Western europe and America. In the near future, it will 
reach russia. A significant improvement in genetic knowl-
edge, especially in the field of predictive medicine, for doctors 
in all specialties is very important for the effective implemen-
tation of the achievements of medical genetics and genomics 
in the russian health care system.
CONCLuSION
thanks to impressive advances in genomics, the emergence 
of new, highly effective methods of molecular analysis, the 
search for marker genes associated with MDs has rapidly 
developed. As a result, (1) thousands of new marker genes, 
the allelic variants of which predispose to the development 
of pathological processes, have been identified; (2) the ge-
netic panels of the most frequent chronic diseases has been 
established; and (3) marker genes defining the severity of the 
disease and predisposition to some complications are being 
identified.
the unprecedented scale of the genotyping of representa-
tives of different races, nationalities, and ethnic groups has 
required hard joint work from clinicians and molecular biolo-
gists. their work has led to numerous DnA databanks con-reVIeWS
 № 3 2009  | ActA nAturAe | 79
taining information on all known mutations and DnA altera-
tions associated with chronic diseases (4).
extensive information on the genotyping of frequent 
chronic diseases among inhabitants of russia has also been 
collected at many russian scientific centers such as the Insti-
tute of Medical Genetics of rAMS (tomsk); Medical Genet-
ics research center (Moscow); Institute of Biochemistry and 
Genetics, Academy of Sciences (ufa); n.I. Vavilov Institute 
of General Genetics, rAS (Moscow); Institute of Molecular 
Genetics, Academy of Sciences (Moscow); and the Institute 
of Molecular Medicine, rAMS, etc.). Only in our laboratory at 
the Ott’s Institute of Obstetrics and Gynecology, rAMS (St. 
Petersburg), has the the frequency of allelic variants of 80 
marker genes in 5,000 patients with different parts of MDs 
and the same number of people from the control group been 
studied.
As an individual DnA database, the genetic passport (GP) 
already exists and is gradually becoming more complex with 
the identification of new genetic markers and the increase in 
the number of gene networks and panels of predisposotion 
genes determining hereditary susceptibility to MDs. If at its 
early stages GP was a fairly simple map including test results 
for approximately 100 marker genes corresponding to gene 
panels of 15-20 frequent chronic MDs, since the emergence 
of the GWAS technology the number of candidate genes has 
grown rapidly. Its characteristic genetic profile correspond-
ing to the distribution in the genome of more than 30-500, 00 
SnP in the SnP map could be determined for each disease 
with the help of this technology. comparison of the genetic 
profiles of sick and healthy patients with that of a particular 
subject provides a high degree of reliability in testing inher-
ited predisposition to the relevant disease.
It is obvious that Gt results have to be treated with great 
caution. the clinical usefulness of such testing, even with 
GWAS technology, still needs to be proved. Of particular 
concern is the lack of information on how and what environ-
mental factors provoke the onset of MDs in a particular per-
son. to this end, the scientific community has already been 
tasked with quantifying the genetic and exogenous risk fac-
tors and their combinations in the pathogenesis of MDs [45]. 
Despite the serious complexity, the implementation of predic-
tive medicine in clinical practice is scientifically founded and 
strategically unavoidable.
In conclusion, let me note that the emergence of new, 
highly efficient methods of DnA sequencing has made it pos-
sible to sequence the full genome of an individual. Massive 
parallel sequencing is particularly promising in this respect 
[46]. recently, it was reported that each American can now 
get his or her whole genome for $ 50,000; ie, 20 times less than 
in 2007. It should be noted, however, that the completely se-
quenced genome of an individual is unlikely to replace the 
genetic passport in the near future. A genetic passport is 
much more convenient and practical in everyday use for a 
clinical geneticist and for a physician using the Gt data. the 
full genome sequence will certainly be important for a more 
in-depth analysis of the unique features of the individual ge-
nome; ie, it can play the role of a universal genetic handbook 
for everyone, while GP will provide information on the status 
of the predisposition genes of several common MDs. It is as-
sumed that within the next 2-3 years, everyone will be able 
to obtain a complete set of his genome for $1,000, and that the 
cost of a genetic passport with the commentary of a specialist 
will cost about $300. Hence, in addition to conventional ma-
jor medical tests and an anthropometric survey, the personal 
medical card of each person will also include the results of 
Gt, the number of which will invariably increase. However, 
according to the opinion of academician V.P. Pusyrev, Gt will 
not replace but will only supplement the results of other labo-
ratory studies [20].
Anticipating such further development, a lot of work on 
the integration of genomics research in the national (pub-
lic) health policy and practice has already been carried out 
in the countries of Western europe and north America. 
Knowledge of the genome seguence has to be integrated 
into the health doctrine of each country, with emphasis on 
predictive medicine. to do this, however, there is still the 
need to figure out what clinical value “high genetic sensitiv-
ity” represents and how to quantify genetic and exogenous 
risks in accordance with the principles of evidence-based 
medicine [45].
the advances of genomics in society and in medicine can 
be accelerated, but it cannot be halted. this fully applies to 
predictive medicine. the introduction of the technology of 
genome-wide screening for the identification of candidate 
genes of MDs, the comparison of the individual profiles of the 
allelic variants of candidate genes of a subject with those of 
sick patients with a particular MD and of obviously healthy 
people supported by the outcomes of prospective genetic test-
ing will open a wide avenue to a new and promising era of 
predictive medicine for humanity. the main task of modern 
genomics is to evaluate the significance of the results of Gt to 
determine the conditions of their implementation in medical 
practice. Possible solutions to this problem in russia include 
the following: (1) a comparison of the obtained Gt results of 
MDs of local populations with international data of their ge-
nome-wide screening, (2) the establishment of representative 
(at least 1,000 samples) DnA banks for each MD, (3) testing of 
new candidate genes on already existing domestic DnA col-
lections, and (4) organizing centers for the implementation of 
genome-wide association screening GWAS.  
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